登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C58H66N10O9 · xC2H4O2
化学文摘社编号:
分子量:
1047.21 (free base basis)
MDL number:
NACRES:
NA.21
Assay:
≥95% (HPLC)
Form:
(Powder or Lyophilized powder or film)
Quality level:
Storage condition:
desiccated
assay
≥95% (HPLC)
form
(Powder or Lyophilized powder or film)
storage condition
desiccated
color
white to off-white
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Somatostatin (SRIF) eptidomimetic with high affinity for somatostatin receptor subtypes STT1/2/3/5 and in vivo efficacy for suppressing GH secretion.
Pasireotide (SOM230) is a somatostatin (somatotropin release inhibiting factor, SRIF) eptidomimetic with high affinity for somatostatin receptor subtypes STT1/2/3/5 (IC50 = 9.3/1/1.5/0.16 nM), but not STT4 (IC50 > 1 μM). SOM230 potently inhibits the growth hormone (GH) releasing hormone (GHRH)-induced GH release in primary rat pituitary cultures (IC50 = 0:4 nM) and suppresses the secretion of GH, insulin and glucagon in rats in vivo (ED50 in μg/kg post 1h administration via s.c. = 0.22, 3.4, 74, respectively; GH ED50 post 6h = 5.5 μg/kg).
Pasireotide (SOM230) is a somatostatin (somatotropin release inhibiting factor, SRIF) eptidomimetic with high affinity for somatostatin receptor subtypes STT1/2/3/5 (IC50 = 9.3/1/1.5/0.16 nM), but not STT4 (IC50 > 1 μM). SOM230 potently inhibits the growth hormone (GH) releasing hormone (GHRH)-induced GH release in primary rat pituitary cultures (IC50 = 0:4 nM) and suppresses the secretion of GH, insulin and glucagon in rats in vivo (ED50 in μg/kg post 1h administration via s.c. = 0.22, 3.4, 74, respectively; GH ED50 post 6h = 5.5 μg/kg).
Disclaimer
Hygroscopic
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持